Clinical Trials · NCT06862908
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Enrollment
- 141
- Start date
- Apr 2025
- Locations
- 1 site, China
- Primary endpoint
- Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)